[The role of gemcitabine in hematology].
In spite of its close chemical similarities with cytarabine, gemcitabine was first evaluated in the treatment of solid tumors. However recent studies performed in patients with hematological malignancies have shown interesting therapeutic potential. Response to single agent gemcitabine have been observed in patients with Hodgkin's disease, cutaneous T cell lymphoma, mantle cell lymphoma, chronic lymphocytic leukemia, and in certain cases of aggressive B cell lymphoma. These preliminary results show high response rates with acceptable toxicity and justify the incorporation of gemcitabine in combination regimens for the treatment of selected lymphoproliferative disorders.
Dumontet
Charles
C
Service d'hématologie, Centre hospitalier Lyon-Sud, 69495 Pierre Bénite. charles.dumontet@chu-lyon.fr
D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D002945:Cisplatin / Q000008:administration & dosage; D002986:Clinical Trials as Topic; D004249:DNA Damage; D004273:DNA, Neoplasm / Q000378:metabolism; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use*; D015195:Drug Design; D019337:Hematologic Neoplasms / Q000188:drug therapy*; D006689:Hodgkin Disease / Q000188:drug therapy; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D016410:Lymphoma, T-Cell, Cutaneous / Q000188:drug therapy; D009101:Multiple Myeloma / Q000188:drug therapy; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors; D009711:Nucleotides / Q000378:metabolism; D012264:Ribonucleotide Reductases / Q000037:antagonists & inhibitors; D016879:Salvage Therapy; D016896:Treatment Outcome; D000093542:Gemcitabine
D000964:Antimetabolites, Antineoplastic; D004273:DNA, Neoplasm; D009363:Neoplasm Proteins; D009711:Nucleotides; D003841:Deoxycytidine; D012264:Ribonucleotide Reductases; D002945:Cisplatin; D000093542:Gemcitabine